Lightbeam Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health management and care coordination platform helping health systems and payers close care gaps and manage high-risk patients. Dallas TX.
About
Lightbeam Health is a population health management company that helps healthcare organizations identify, stratify, and engage high-risk patients to improve outcomes and reduce costs in value-based care arrangements. Headquartered in Dallas, Texas, Lightbeam serves health systems, ACOs, and health plans with a platform that aggregates clinical and claims data, applies predictive risk models, and delivers actionable patient lists to care management teams. The company has a strong presence in the ambulatory care market and among organizations pursuing Medicare Shared Savings Program and Medicare Advantage contracts.\n\nLightbeam's platform includes a comprehensive care management workflow tool that allows care coordinators to document interventions, manage care plans, and track outcomes across attributed patient populations. The system integrates with major EHR platforms to deliver real-time clinical context alongside population-level analytics, enabling care managers to move from insight to action without leaving their primary workflow environment. Lightbeam also supports quality measure tracking for HEDIS, CMS Stars, and commercial quality programs, giving organizations a single platform for both care management operations and performance reporting.\n\nThe company has grown through a combination of organic expansion and strategic partnerships with health IT ecosystem players. Lightbeam competes with vendors like Arcadia, Innovaccer, and Zeomega in the population health space, differentiating on depth of care management functionality and configurability for diverse organizational structures including large physician groups and independent practice associations.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.